Congress Instructs FDA On Nanotech Work, But Mute On Funding
This article was originally published in The Rose Sheet
Newly passed user-fee legislation includes a provision directing FDA to intensify its research and policy development regarding nanotechnology and its use in consumer products. How such efforts are to be funded remains a question.
You may also be interested in...
FDA Global Panel Focuses On Developing Countries’ Reg Systems
An FDA Science Board subcommittee will assess safety awareness in countries exporting food and medical products to the U.S. and identify potential strategies for strengthening regulatory systems in those countries, says Chairman Jeff Bender.
Safety Testing For Nano-Cosmetics Must Address Actual Use Scenarios
Study on powder-based cosmetics self-identified as incorporating nanotechnology finds that nanomaterials released through product use and inhaled do not deposit in the respiratory system where one might expect them to. Investigators conclude that marketers must take into consideration not only the safety of pure nano-ingredients but also their fate with actual product use.
House, Senate Differ In Treating FDA China Syndrome
Appropriators in the House and Senate endorse FDA’s plan to spend $10 million more on inspections in China in 2013, but only the Senate approves increasing the agency’s budget to cover the costs. FDA’s request for China inspections includes $5.6 million for inspections at drug facilities.